NCT03540563View on ClinicalTrials.gov

ctDNA as a Biomarker for Treatment Response in HNSCC

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 16, 2018

Primary Completion Date

August 1, 2023

Study Completion Date

August 1, 2023

Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
OTHER

Blood draw

Blood will be drawn to assess ctDNA

Trial Locations (1)

1066CX

Antoni van Leeuwenhoek, Amsterdam

All Listed Sponsors
lead

The Netherlands Cancer Institute

OTHER

NCT03540563 - ctDNA as a Biomarker for Treatment Response in HNSCC | Biotech Hunter | Biotech Hunter